Persistent Lower Abdominal Pressure and Discomfort After Lithotripsy: What’s Going On?

Patients who experience persistent lower abdominal pressure or a sensation of heaviness following extracorporeal shock wave lithotripsy (ESWL) may be encountering one or more common post-procedural phenomena. This discomfort—often described as “dragging,” “fullness,” or “aching”—typically arises from transient physiological responses rather than serious complications.

One frequent cause is ureteral stent-related irritation, especially if a double-J (DJ) stent was placed prophylactically before or after ESWL to facilitate stone fragment passage and prevent obstruction. Stents can induce bladder irritation, referred pelvic pressure, and mild ureteral spasm, all contributing to persistent lower abdominal discomfort.

Another explanation is the presence of residual stone fragments—particularly small, impacted fragments in the distal ureter—that trigger localized inflammation, ureteral peristaltic hyperactivity, or partial obstruction. Even subclinical obstruction can stimulate stretch receptors in the urinary tract wall, generating a sensation of fullness or dragging.

Post-ESWL inflammatory changes—including edema of the renal pelvis, calyces, or ureteral mucosa—may also contribute. The mechanical trauma induced by shock waves triggers a localized inflammatory cascade, which can persist for several days and manifest as dull, non-radiating lower abdominal discomfort.

Less commonly, persistent symptoms may signal complications such as urinary tract infection (especially if accompanied by fever, dysuria, or cloudy urine), hematoma formation, or, rarely, ureteral stricture. Therefore, clinical evaluation—including urinalysis, renal ultrasound, and, when indicated, non-contrast CT—is essential if symptoms last beyond 5–7 days, worsen, or are associated with systemic signs.

Management is typically conservative: increased oral hydration, judicious use of alpha-blockers (e.g., tamsulosin) to promote fragment clearance, and short-term NSAIDs for symptomatic relief. Patients should be counseled that mild, self-limiting discomfort is expected, but sustained or progressive symptoms warrant timely urologic reassessment.